96 related articles for article (PubMed ID: 3499037)
1. Comparison of the thrombolytic efficacy of defibrase and urokinase on canine coronary artery thrombosis and the mechanism of urokinase-induced hemorrhage.
Huang DX; Song A; Yang X; Wang S
Acta Cardiol; 1987; 42(4):249-61. PubMed ID: 3499037
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of the efficacy of intravenous urokinase and defibrase on 6-hour-old canine coronary thrombosis].
Huang DX; Song AL; Yang XS
Zhonghua Xin Xue Guan Bing Za Zhi; 1988 Dec; 16(6):363-5, 384. PubMed ID: 3248518
[No Abstract] [Full Text] [Related]
3. Preventive effects of batroxobin on experimental canine coronary thrombosis.
Tomaru T; Uchida Y; Sonoki H; Sugimoto T
Clin Cardiol; 1988 Apr; 11(4):223-30. PubMed ID: 3163298
[TBL] [Abstract][Full Text] [Related]
4. Enhanced myocardial salvage by combined treatment with recombinant single-chain urokinase-type plasminogen activator and recombinant human superoxide dismutase in a canine coronary thrombosis model.
Fincke U; Schneider J; Friderichs E; Giertz H; Flohé L
Arzneimittelforschung; 1988 Jan; 38(1):138-42. PubMed ID: 3365272
[TBL] [Abstract][Full Text] [Related]
5. The thrombolytic effects of native tissue-type plasminogen activator (AK-124) on experimental canine coronary thrombosis.
Tomaru T; Uchida Y; Sonoki H; Tsukamoto M; Sugimoto T
Angiology; 1989 May; 40(5):429-35. PubMed ID: 2495745
[TBL] [Abstract][Full Text] [Related]
6. [Effectiveness of urokinase used in combination with batroxobin (DF-521) in rat model of focal cerebral ischemia-reperfusion].
Hu XS; Zhou D; Hu XY; Zhang YZ; Tian LY; Huang J
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 May; 35(3):395-7. PubMed ID: 15181847
[TBL] [Abstract][Full Text] [Related]
7. Heparin requirement in tissue-type plasminogen activator-induced experimental coronary thrombolysis: comparison with urokinase-induced coronary thrombolysis.
Susawa T; Yui Y; Hattori R; Takahashi M; Aoyama T; Takatsu Y; Sakaguchi K; Yui N; Kawai C
Jpn Circ J; 1987 Apr; 51(4):431-5. PubMed ID: 2441082
[TBL] [Abstract][Full Text] [Related]
8. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of thrombolytic and systemic effects of the novel recombinant plasminogen activator BM 06.022 compared with alteplase, anistreplase, streptokinase and urokinase in a canine model of coronary artery thrombosis.
Martin U; Sponer G; Strein K
J Am Coll Cardiol; 1992 Feb; 19(2):433-40. PubMed ID: 1732372
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of tissue plasminogen activator and urokinase in a canine model of prosthetic graft thrombosis.
Curl GR; Jakubowski JA; Nabseth DC; Bush HL
Arch Surg; 1986 Jul; 121(7):782-8. PubMed ID: 3087327
[TBL] [Abstract][Full Text] [Related]
11. Thrombolysis with recombinant human single-chain urokinase-type plasminogen activator (rscu-PA): dose-response in dogs with coronary artery thrombosis.
Van de Werf F; Jang IK; Collen D
J Cardiovasc Pharmacol; 1987 Jan; 9(1):91-3. PubMed ID: 2434801
[TBL] [Abstract][Full Text] [Related]
12. Comparative studies of thrombolysis with single-chain and two-chain recombinant tissue-type plasminogen activators in canine coronary thrombosis.
Yokoyama M; Ichikawa Y; Yatani A; Matsui K; Nakahara H; Kaneko M; Sakurama T; Ueshima S; Matsuo O
J Cardiovasc Pharmacol; 1996 Oct; 28(4):571-5. PubMed ID: 8891884
[TBL] [Abstract][Full Text] [Related]
13. The effect of intravenous infusion of urokinase on coronary artery thrombolysis in the dog.
Isojima K; Sato Y; Lew A; Ganz W
Jpn Circ J; 1985 Nov; 49(11):1195-200. PubMed ID: 4094039
[TBL] [Abstract][Full Text] [Related]
14. The beneficial effect of lys-plasminogen upon the thrombolytic efficacy of urokinase in a dog model of peripheral arterial thrombosis.
Badylak SF; Voytik SL; Henkin J; Burke S; Sasahara AA; Simmons A
Haemostasis; 1991; 21(5):278-85. PubMed ID: 1806456
[TBL] [Abstract][Full Text] [Related]
15. Additional myocardial salvage by coadministration of the epoprostenol analog taprostene to recombinant single-chain urokinase-type plasminogen activator in a canine coronary thrombosis model.
Groves R; Schneider J; Friderichs E; Giertz H; Flohé L
Arzneimittelforschung; 1989 Apr; 39(4):534-8. PubMed ID: 2665759
[TBL] [Abstract][Full Text] [Related]
16. [Intracoronary thrombolytic therapy in Kawasaki disease and the usefulness of two-dimensional echocardiography in detecting intracoronary thrombi].
Ichinose E; Kato H; Inoue O; Hirata K; Eto Y; Yoshioka F
J Cardiogr; 1985 Mar; 15(1):79-87. PubMed ID: 4067350
[TBL] [Abstract][Full Text] [Related]
17. Thrombolytic effects of intracoronary streptokinase on canine coronary artery thrombosis.
Fiedler VB
Basic Res Cardiol; 1984; 79(1):17-26. PubMed ID: 6732717
[TBL] [Abstract][Full Text] [Related]
18. Indications for and limitations of coronary thrombolysis.
Kanmatsuse K; Kajiwara N; Onikura S; Satoh Y; Andoh T
Jpn Circ J; 1985 Jun; 49(6):597-604. PubMed ID: 3162042
[TBL] [Abstract][Full Text] [Related]
19. Fiberoptic study on the effects of transluminal angioplasty in experimental occlusive arterial thrombosis.
Tomaru T; Uchida Y; Sugimoto T
Am Heart J; 1988 Feb; 115(2):312-7. PubMed ID: 2963513
[TBL] [Abstract][Full Text] [Related]
20. Management of complicated coronary angioplasty by intracoronary urokinase and immediate re-angioplasty.
Verna E; Repetto S; Boscarini M; Onofri M; Qing LG; Binaghi G
Cathet Cardiovasc Diagn; 1990 Feb; 19(2):116-22. PubMed ID: 2106394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
